Trends
Genome-wide association studies (GWASs) have highlighted genetic variants in the CHRNA5-CHRNA3-CHRB4 gene cluster associated with smoking heaviness and nicotine dependence as well as known smoking-related diseases such as chronic obstructive pulmonary disease (COPD) and lung cancer.
Animal studies have described the anatomy and function of the nicotinic acetylcholine receptor (nAChR) subunits encoded by the CHRNA5-CHRNA3-CHRB4 gene cluster.
More in-depth phenotyping in humans is improving our understanding of how these variants contribute to smoking behaviour.
Use of this gene cluster in Mendelian randomisation analyses is enabling us to investigate the causal effects of tobacco use. The latest findings suggest that smoking heaviness could be a causal factor for schizophrenia.
Validated genetic targets emerging from GWASs that influence smoking behaviour may pave the way towards individually tailored smoking cessation treatments, ultimately reducing the burden of smoking-related diseases. 
Glossary
Amino acid: the subunit that, joined together with other amino acids, forms a protein.
Candidate gene association study: a study in which a specific genetic variant is selected because of its perceived biological relevance to the phenotype of interest (i.e., hypothesis driven 
From GWAS to Neurobiology
Smoke inhaled from a cigarette is a mixture of chemicals [ 8 4 _ T D $ D I F F ] that travel through the airways to the lungs. Nicotine is the primary addictive constituent of cigarette smoke; it is absorbed by the alveolar epithelium and then circulates in the bloodstream. Nicotine is an exogenous ligand for nAChRs and binds, after crossing the blood-brain barrier, to nAChRs ubiquitously expressed in the brain ( Figure 1C Furthermore[ 1 0 3 _ T D $ D I F F ] , [8] also showed that this effect could be 'rescued' in /5 knockout mice through the injection of a lentivirus vector into the medial habenula (MHb), rescuing expression of /5 subunits in this region. The knockout mice did not appear to differ from wild-type mice in their experience of the rewarding effects of nicotine, but the inhibitory effect of high nicotine doses on the activity of reward circuitries observed in wild-type mice appeared to have been largely [9] where the differential effects of nicotine dose on reward between /5 knockouts and wild-types was illustrated using a conditioned [ 1 0 7 _ T D $ D I F F ] place-preference task. In addition, a recent study in humans [10] found an attenuated aversive response to [ 1 0 8 _ T D $ D I F F ] intravenously administrated nicotine in overnightabstinent smokers who were carriers of the CHRNA5 rs16969968 risk allele genotype. The MHb mainly projects to the interpeduncular nucleus (IPN)[ 1 0 9 _ T D $ D I F F ] and [8] observed that diminished IPN activity in response to nicotine was seen in knockout mice. In short, it appears that high doses of nicotine stimulate the MHb-IPN tract through nAChRs containing /5 subunits and elicit aversion, limiting further intake. This does not [ 1 1 0 _ T D $ D I F F ] occur when /5 signalling is deficient and consequently the negative effects of nicotine are attenuated. Similarly, smokers carrying the rs16969968 risk allele are therefore more likely to smoke more heavily than their counterparts without the risk allele.
The study reported in [11] 
Measuring Smoking Behaviour
As we have seen, the first major results of [13] . The lack of compensatory behaviour in risk allele carriers when smoking cigarettes with higher levels of nicotine is analogous to the reduced aversive effect of nicotine observed in /5 knockout mice [8] . are more strongly associated with levels of cotinine than CPD. This was subsequently confirmed in an extensive meta-analysis[ 1 7 8 _ T D $ D I F F ] : there is a much stronger signal for the association between the CHRNA5-A3-B4 genotype and heaviness of smoking when this is captured by cotinine levels (4% of phenotypic variation explained) rather than CPD (1% variation explained). Interestingly, the association with cotinine levels remains when CPD is statistically adjusted for in the analysis [15, 16] .
These findings highlight the need for more precise phenotypic measures. However 
CPD
CPD is the count of cigarettes smoked in one day[ 6 0 2 _ T D $ D I F F ] from waking up to going to bed. This phenotype has been used in several studies [2, 50, 51] .
Questionnaires
The more cigarette and [ 1 9 4 _ T D $ D I F F ] show a 138 nmol/l mean increase in cotinine levels for each copy of the rs16969968 minor allele that they may carry [16] . By recalling participants according to rs16969968 genotype (i.e., the two homozygote groups)[ 1 9 5 _ T D $ D I F F ] , we can capture the greatest phenotypic difference in smoking heaviness resulting from genetic difference at the CHRNA5-A3-B4 locus ( Figure 1B ). As we [ 1 9 6 _ T D $ D I F F ] see in the next section, this approach captures many of the features of a never-smokers, suggesting that heavier smoking causally lowers body weight. The finding has been replicated and extended to other measures of adiposity (e.g., waist circumference) in subsequent MR analyses [23] [24] [25] . Similar analyses have shown that smoking leads to higher resting heart rate and may adversely affect kidney function, as it leads to higher estimated glomerular filtration rate [25, 26] , as well as all-cause mortality [27] .
MR has also highlighted observational associations that may not be causal. Despite strong links between smoking and mental health, MR studies have not found evidence that the minor allele of It is important to note that new methods for the undertaking of MR analyses are able to account for violations of these assumptions and to quantify the extent of the likely biases induced by failures to satisfy them [55, 56] .
[ 6 6 4 _ T D $ D I F F ] While it is not possible to fully test these assumptions, knowledge of the biology of the CHRNA5-CHRNA3-CHRNB4 gene cluster, including the identification of the functionally significant SNP[ 6 6 7 _ T D $ D I F F ] rs16969968 and its role in determining response to nicotine, strengthens the validity of variants in this gene cluster as instruments for MR analyses.
The rs16969968 (or rs1051730) variant has been used to investigate whether associations between smoking and several health outcomes are causal. As the variant is associated with smoking heaviness rather than smoking initiation, it is used as an instrument for smoking heaviness within smokers and findings of MR studies using this variant do not directly tell us whether being a smoker causes a particular disease. However, using rs16969968 as an instrument for smoking heaviness rs16969968 is associated with higher levels of depression in smokers [28] [29] [30] , suggesting that smoking does not cause depression. Lack of associations of rs16969968 with blood pressure, serum lipids[ 2 4 7 _ T D $ D I F F ] , and glucose levels [ 2 4 8 _ T D $ D I F F ] indicate that smoking may not causally influence these cardiometabolic traits [25, 26] . [33] [34] [35] . As the GWAS was not conducted stratified by smoking status, it is difficult to distinguish between these two possibilities; however, a recent MR analysis [29] , which was stratified by smoking status, provides supportive evidence for a causal effect of smoking on schizophrenia. They found that the minor allele of rs1051730 was associated with higher odds of being prescribed Other observational studies and meta-analyses have provided convergent evidence for the association between schizophrenia (and psychotic illness more generally) and smoking behaviour [36] [37] [38] .
One limitation of the MR approach is that it typically requires very large sample sizes, because genetic variants for common traits generally only explain a very small proportion of phenotypic variation. Therefore, many MR studies combine data from multiple studies to increase [ 2 7 9 _ T D $ D I F F ] their power to detect effects (e.g., [28] ). A further solution is to perform MR analysis [ 2 8 0 _ T D $ D I F F ] on samples of individuals recalled and phenotyped on the basis of genotype. As discussed above, this [ 2 8 1 _ T D $ D I F F ] maximises genetic differences (and therefore differences in phenotypic exposure) between individuals. In the case of CHRNA5-A3-B4, selecting only homozygotes for rs16969968 increases [ 2 8 4 _ T D $ D I F F ] the power to detect causal effects of smoking [17] . Investigating the causal effects of the genotype-phenotype relationship is key to progress[ 2 8 6 _ T D $ D I F F ] in the identification of human genetic targets for smoking treatment.
From Genetics to Therapeutics
The treatment of nicotine dependence remains a significant unmet medical need given the limited efficacy of behavioural and pharmacological Human genetics findings in nicotine dependence and smoking heaviness may reveal novel targets for medication[ 3 0 8 _ T D $ D I F F ] development or even highlight novel brain substrates within which such targets are expressed. However, neither of the studies described above appears to have [ 3 0 9 _ T D $ D I F F ] utilised human genetics to identify the target or to set inclusion criteria and thereby stratify patient populations to identify those most likely to demonstrate a positive response to treatment [40, 41] . Nevertheless, it is clear that [ [6, 45, 46] , it is reasonable to predict that novel chemical entities that enhance activity of a5* nAChRs will decrease tobacco use [8, 10] . Moreover, the neuronal [ 3 2 9 _ T D $ D I F F ] circuits in which /5* nAChRs that regulate nicotine intake may reside, and other genes associated with risk of nicotine dependence, are also likely to contain novel targets for medication [ [5, 11] . Given the observed reduction in activity of the D398N /5 nAChR, it seems logical to begin the identification of selective ligands that enhance [ 3 3 5 _ T D $ D I F F ] nAChR function (i.e., agonists; Figure 1D ).[ 3 3 6 _ T D $ D I F F ] However, the highly conserved nature of the orthosteric site among[ 3 3 7 _ T D $ D I F F ] nicotinic acetylcholine receptor subunits makes it challenging to identify orthosteric ligands with optimal selectivity and physiochemical properties [47] .[ 3 3 8 _ T D $ D I F F ] Therefore, an alternative approach is to look for selective positive allosteric modulators of the /5 subunit, perhaps by targeting key habenular circuits. This could be achieved either by restoring appropriate cholinergic tone and the aversive or [ 3 3 9 _ T D $ D I F F ] reward-attenuating properties of nicotine in a genetically insensitive population[ 3 4 0 _ T D $ D I F F ] or by increasing it in the normal population [ 3 4 1 _ T D $ D I F F ] to reduce [ 3 4 2 _ T D $ D I F F ] daily nicotine intake [5] . [1, 2, 6, 48, 49] . Whether the same genes are associated with mental health is still disputed[ 3 5 2 _ T D $ D I F F ] , although the latest findings suggest that smoking heaviness and schizophrenia share some genetic liability [35, 38] . The advances in phenotyping (e.g., by employing precise biomarker assessments), together with the fast development of DNA and RNA sequencing technologies and powerful analytical
Concluding Remarks and Future Perspectives

Outstanding Questions
Will human GWASs, in parallel with experiments in preclinical (e.g., rodent) models and human studies, allow us to go beyond the known neurobiology of smoking behaviour and provide genuinely novel mechanistic insights?
Will biomarkers (e.g., cotinine) allow us to both gain information about the role of target genes and anticipate the response to treatments targeting the corresponding gene products?
Will insights into gene-to-phenotype causal relationships lead to novel treatments for smoking cessation? Do schizophrenia and heavy smoking share an underlying genetic liability or is smoking causally related to schizophrenia risk or other mental health conditions?
Will increasing the reward-attenuating properties of nicotine enhance treatment response in a well-defined population of smokers?
